Llwytho...
How I treat relapsed and/or refractory multiple myeloma
The expanding therapeutic landscape of relapsed and/or refractory multiple myeloma (RRMM) has contributed to significant improvements in patient outcomes. These have included combinations of proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), monoclonal antibodies (mAbs), histone deacetylas...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Hematol Rep |
|---|---|
| Prif Awduron: | , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
PAGEPress Publications, Pavia, Italy
2020
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7520845/ https://ncbi.nlm.nih.gov/pubmed/33042504 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4081/hr.2020.8955 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|